Deltec Asset Management LLC Buys Shares of 15,756 Jade Biosciences, Inc. $JBIO

Posted by Geri Gentry on Oct 1st, 2025

Deltec Asset Management LLC bought a new stake in Jade Biosciences, Inc. (NASDAQ:JBIO – Free Report) during the second quarter, HoldingsChannel.com reports. The fund bought 15,756 shares of the company’s stock, valued at approximately $157,000.

Analysts Set New Price Targets

A number of research analysts have recently commented on JBIO shares. Jefferies Financial Group began coverage on shares of Jade Biosciences in a research note on Monday, July 14th. They set a “buy” rating and a $16.00 price objective for the company. Wall Street Zen downgraded shares of Jade Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 16th. Wedbush increased their price objective on shares of Jade Biosciences from $17.00 to $18.00 and gave the company an “outperform” rating in a research report on Thursday, August 14th. Finally, Guggenheim upgraded Jade Biosciences from a “neutral” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Monday, June 16th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $16.00.

Get Our Latest Analysis on JBIO

Jade Biosciences Price Performance

Shares of JBIO opened at $8.63 on Wednesday. The firm has a market capitalization of $281.60 million, a price-to-earnings ratio of -0.28 and a beta of 1.04. Jade Biosciences, Inc. has a one year low of $6.57 and a one year high of $105.00. The company’s fifty day simple moving average is $7.67.

Jade Biosciences (NASDAQ:JBIO – Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.43).

Jade Biosciences Profile

(Free Report)

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.